Clinical Trial Update: A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) [Phase 3]

View source ↗

Summary

Phase 3 trial update for V503 (9-valent HPV vaccine) in females 12-26 who previously received GARDASIL; study completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancers, Vulvar Cancers | Phase 3 | Status: COMPLETED | Results posted: 2014-12-22